Teva acquired Allergan's global generics business (formerly Actavis Generics) for approximately $40.5 billion in cash and stock, becoming the world's largest generics pharmaceutical company by revenue with over 1,000 generic molecules across all major markets.
Key facts
AnnouncedJul 27, 2015
ClosedAug 02, 2016
Deal value$40.5B
Deal typeAsset Purchase
Therapeutic areaCardiovascular, Neurology, Oncology, Respiratory, Women's Health
IndicationsMultiple therapeutic areas (generic portfolio)
Key assetsActavis global generics portfolio (~1,000 molecules), Anda generic distribution business, Global manufacturing network (over 40 facilities), Generics pipeline (~300 pending ANDAs), International generics operations (60+ countries), Generic portfolio
MechanismMultiple (generic portfolio spanning all major drug classes)